What is it about?
Vascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy. The discovery of anti-VEGF agents has revolutionized the treatment of these conditions. Ophthalmology has witnessed an explosion in the number of intravitreal injections delivered to patients over the past 10 years, driven in large part by the introduction and rapid incorporation of therapy with anti-VEGF agents. Currently several anti-angiogenic agents are being widely and successfully used for the treatment of eye diseases. However, there is some evidence that intravitreal antiangiogenics injections may result in injection-related ocular side effects. This mandates an awareness on the matter.
Featured Image
Why is it important?
Currently several anti-angiogenic agents are being widely and successfully used for the treatment of eye diseases. However, there is some evidence that intravitreal antiangiogenics injections may result in injection-related ocular side effects. This mandates an awareness on the matter.
Perspectives
Search for new more safe therapeutic agents with multiple mechanism of action
Prof., Dr Marianne M Shahsuvaryan
Yerevan State Medical University Named after Mkhitar Heratsi
Read the Original
This page is a summary of: Pharmacovigilance in Intraocular Antiangiogenic Therapy, International Journal of Ophthalmic Research, January 2015, ACT Publishing Group,
DOI: 10.17554/j.issn.2409-5680.2015.01.13.
You can read the full text:
Contributors
The following have contributed to this page
